Menu Expand
Consultative Hematology, An Issue of Hematology/Oncology Clinics of North America - E-Book

Consultative Hematology, An Issue of Hematology/Oncology Clinics of North America - E-Book

Fred J. Schiffman | Anthony Mega

(2012)

Additional Information

Book Details

Abstract

Topics include: Why does my patient have leukocytosis?, Why Is My Patient Neutropenic?, Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?, DVT and Pulmonary Embolism, Why Does My Patient Have Lymphadenopathy/Splenomegaly?,and Why Does My Patient have Thrombocytopenia?

Table of Contents

Section Title Page Action Price
Front Cover Cover
Hematology/Oncology Clinics of North America i
Copyright Page ii
Table of Contents vii
Contributors iii
Preface xiii
Chapter 1. Why is My Patient Anemic? 205
WHAT IS ANEMIA? 206
WHAT ARE THE DETERMINANTS OF HEMOGLOBIN CONCENTRATION? 206
WHAT ARE THE CONSEQUENCES OF ANEMIA? 209
SUMMARY 209
WHY IS MY PATIENT ANEMIC? 209
RED BLOOD CELL (RBC) LOSS OR DILUTION ANEMIA 212
RED BLOOD CELL (RBC) PRODUCTION 220
ANEMIA OF INFLAMMATION 225
SUMMARY 226
REFERENCES 227
Chapter 2. Why Does My Patient Have Thrombocytopenia? 231
PERTINENT HISTORY IN THE PATIENT WITH THROMBOCYTOPENIA 231
PHYSICAL EXAMINATION 231
ANCILLARY TESTS 232
MECHANISMS OF THROMBOCYTOPENIA 234
THROMBOCYTOPENIA IN THE INTERNAL MEDICINE PATIENT 237
DRUG-INDUCED THROMBOCYTOPENIA 239
POSTTRANSFUSION PURPURA 242
THROMBOCYTOPENIA ASSOCIATED WITH INFECTIONS 243
THROMBOCYTOPENIA IN THE INTENSIVE CARE UNIT 243
THROMBOCYTOPENIA IN THE PATIENT WITH A HEMATOLOGIC MALIGNANCY 246
THROMBOCYTOPENIA IN THE SOLID TUMOR PATIENT 246
THROMBOCYTOPENIA IN THE STEM CELL AND SOLID ORGAN TRANSPLANT PATIENT 247
SUMMARY 247
REFERENCES 247
Chapter 3. Why is My Patient Neutropenic? 253
NEUTROPHIL OVERVIEW 253
NEUTROPENIA 253
DIAGNOSTIC WORKUP 254
CAUSES 255
ETHNIC VARIATION 255
CONGENITAL NEUTROPENIA 255
IMMUNE-RELATED NEUTROPENIA 257
DRUGS 260
INFECTIONS 262
MALIGNANCY 263
SUMMARY 264
REFERENCES 264
Chapter 4. Why Does My Patient Have Erythrocytosis? 267
REGULATION OF ERYTHROPOIESIS 268
RELATIVE POLYCYTHEMIAS 269
ABSOLUTE POLYCYTHEMIAS 269
SUMMARY 278
REFERENCES 279
Chapter 5. Why Does My Patient Have Thrombocytosis? 285
REACTIVE THROMBOCYTOSIS (RT) 285
ESSENTIAL THROMBOCYTOSIS (ET) AND MYELOPROLIFERATIVE STATES 288
POLYCYTHEMIA VERA (PV) 295
CHRONIC MYELOGENOUS LEUKEMIA (CML) 295
PRIMARY MYELOFIBROSIS 296
SUMMARY 296
REFERENCES 296
Chapter 6. Why Does My Patient Have Leukocytosis? 303
WHITE BLOOD CELL (WBC) DEVELOPMENT 303
DEVELOPMENT, MATURATION, AND SURVIVAL OF GRANULOCYTES 304
DEVELOPMENT OF MONOCYTES 304
LYMPHOCYTE DEVELOPMENT 305
EVALUATION OF LEUKOCYTOSIS 305
CLASSIFICATION OF LEUKOCYTOSIS 305
DISTINGUISHING A PRIMARY HEMATOLOGIC DISORDER FROM A REACTIVE (SECONDARY) LEUKOCYTOSIS 306
CAUSES OF SECONDARY LEUKOCYTOSIS 306
HEMATOLOGIC MALIGNANCIES 312
DIAGNOSTIC WORKUP OF LEUKOCYTOSIS 315
SUMMARY 317
REFERENCES 317
Chapter 7. Why Is My Patient Bleeding Or Bruising? 321
PATIENT HISTORY 322
PHYSICAL EXAMINATION 325
CLINICAL MANIFESTATIONS 325
LABORATORY TESTING 328
DIAGNOSTIC ALGORITHM AND DIFFERENTIAL DIAGNOSIS 332
SUMMARY 340
REFERENCES 341
Chapter 8. Venous Thromboembolism Overview 345
VENOUS THROMBOEMBOLISM (VTE): PRESENTATION 347
VENOUS THROMBOEMBOLISM (VTE): DIAGNOSIS 347
VENOUS THROMBOEMBOLISM (VTE): INITIAL TREATMENT 348
DURATION OF ANTICOAGULATION THERAPY 349
NEW ORAL ANTICOAGULANTS 354
SUPERFICIAL VENOUS THROMBOSIS 355
TRAVEL-RELATED VENOUS THROMBOSIS 357
HYPERCOAGULABLE WORK-UP 358
BRIDGING: ANTICOAGULATION BRIDGING FOR INVASIVE PROCEDURES 359
SUMMARY 361
REFERENCES 362
Chapter 9. Does My Patient Have a Life- or Limb-Threatening Thrombocytopenia? 369
DISEASE ENTITIES 369
SUMMARY 380
REFERENCES 380
Chapter 10. Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma? 383
EPIDEMIOLOGY OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE 383
DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) 385
RISK FACTORS FOR PROGRESSION AND STRATIFICATION MODELS FOR PATIENTS WITH MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) 385
EPIDEMIOLOGY AND DIAGNOSTIC CRITERIA FOR SMOLDERING MULTIPLE MYELOMA (SMM), MULTIPLE MYELOMA (MM), AND PLASMA CELL (PC) DYSCRASIA VARIANTS 386
CLINICAL PRESENTATION OF MULTIPLE MYELOMA (MM) 387
SUSPECTING MULTIPLE MYELOMA (MM) IN A PATIENT WITH A MONOCLONAL SPIKE (M SPIKE) 387
DIAGNOSTIC INVESTIGATIONS IN PATIENTS WHOSE MONCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) EVOLVES INTO MULTIPLE MYELOMA (MM) 389
THE IMPORTANCE OF AN EARLY DIAGNOSIS OF MULTIPLE MYELOMA (MM) 390
SUMMARY AND REMARKS 390
REFERENCES 390
Chapter 11. Why Does My Patient Have Lymphadenopathy or Splenomegaly? 395
MECHANISMS OF LYMPHADENOPATHY 395
MECHANISMS OF SPLENOMEGALY 396
LOCATION OF LYMPHADENOPATHY 396
EVALUATION OF LYMPHADENOPATHY 400
LYMPH NODE CHARACTERISTICS 402
LYMPH NODE SIZE AND BIOPSY CONSIDERATIONS 402
SPLENOMEGALY 402
WHEN SHOULD AN ENLARGED SPLEEN BE REMOVED 405
SUMMARY 405
REFERENCES 405
Chapter 12. Special Hematologic Issues in the Pregnant Patient 409
ANEMIA 409
THROMBOCYTOPENIA 413
PLATELET FUNCTION DISORDERS 416
VON WILLEBRAND DISEASE (VWD) AND OTHER BLEEDING DISORDERS 417
THROMBOPHILIA AND THROMBOEMBOLISM 421
HEMATOLOGIC MALIGNANCIES 427
SUMMARY 428
REFERENCES 428
Index 433